Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening dosing of DuoTrav in primary open angle glaucoma or ocular hypertension
2007-002501-45Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Intraocular pressure at 9:00, 11:00 and 16:00. Started Jan 2008; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2007-002501-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002501-45.